ELAVL1 and esophageal cancer: The in vitro results showed that angustoline activated the expressions of LKB1 and AMPK and subsequently inhibited the levels of ELAVL1 and LPCAT2 (Figures 4B,C,E,F), which elucidated the anti-tumor mechanism of angustoline in esophageal cancer cell model.